Kronos Bio, Inc.
kronosbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 8, 2025. Its latest SEC filing is a 15-12G from Jun 30, 2025.
10-Q for Q1 FY2025, filed May 8, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops small-molecule therapeutics that address deregulated transcription in cancer and autoimmune disease.
10-K for FY2024, filed Mar 18, 2025We are a biopharmaceutical company that has historically focused on the discovery and development of small molecule therapeutics that…View ↗
Our mechanistic insights into the p300 and IRF4 critical node relationship motivated the internal optimization and of our novel series of…View ↗
Leveraging the findings that p300 KAT inhibitors had in multiple myeloma, a plasma cell driven disease, we made the decision to pursue…View ↗
How Did They Make Money?
Partners pay upfront fees for licenses and research collaborations, may make milestone payments, and may owe royalties on product sales; research-service fees are earned as work progresses.
10-K for FY2024, filed Mar 18, 2025The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance…View ↗
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when…View ↗
Pursuant to the agreement, we received an upfront payment of $20.0 million from Genentech. In addition, we were eligible for additional…View ↗
$9.8M
-
10-K for FY2024, filed Mar 19, 2025
$9.8M ↗
Who Were Their Customers?
Kronos worked directly with Genentech on oncology discovery programs: Kronos led the discovery work, while Genentech could take selected compounds into further development and commercialization.
10-K for FY2024, filed Mar 18, 2025
Did Revenues Turn Into Profits?
No. It lost $86.1M in FY2024.
10-K for FY2024, filed Mar 19, 2025
−$92.9MView ↗
10-K for FY2024, filed Mar 19, 2025
−$86.1MView ↗
10-K for FY2024, filed Mar 19, 2025
−$65.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 9, 2025
−$8.4MView ↗
- ▼ −72% (Loss)
- vs −$30M in Q1 FY2024
-
Jun 20, 2025
Concentra completed its acquisition of Kronos Bio
Shareholders received $0.57 per share in cash plus a contingent value right tied to asset-sale proceeds and cost savings; Kronos became Concentra's wholly owned subsidiary.
Sources
8-K, filed Jun 20, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on June 20, 2025, Merger Sub completed a tender…View ↗
Toward a strategic transaction
The older report described ongoing clinical trials and discovery programs. The latest says clinical, research, and development activities were suspended while the company explored a sale, merger, asset divestiture, licensing, or another strategic transaction.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Mar 18, 2025Following the decision by our Board of Directors in November 2024 to assess our strategic alternatives, suspend clinical, research, and…View ↗
A different therapeutic focus
The older report emphasized AML and solid-tumor programs; the latest describes candidates for multiple myeloma and Sjogren’s disease, while stating that the istisociclib clinical trial was discontinued.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Mar 18, 2025Our lead product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that has been…View ↗
Our lead product candidate, entospletinib, is a selective inhibitor of SYK, a critical node in a dysregulated TRN within AML defined by…View ↗
KB-0742, generated from our product engine’s SMM platform is a highly selective, oral CDK9 inhibitor being developed to treat MYC-amplified…View ↗
In November 2024, we announced the discontinuation of our clinical trial for istisociclib (KB-0742), our internally discovered oral cyclin…View ↗
Our mechanistic insights into the p300 and IRF4 critical node relationship motivated the internal optimization and of our novel series of…View ↗
Leveraging the findings that p300 KAT inhibitors had in multiple myeloma, a plasma cell driven disease, we made the decision to pursue…View ↗
Loading...
